Exhibit 10

From: Herbert, Dellarese L < Dellarese.Herbert@fda.hhs.gov>

Sent:Tuesday, February 19, 2019 7:23 AMTo:Megha Shah; ORA PHARM1 RECALLS

Cc: Jeffrey Jackowski; Dan Burns; Jasleen Gupta; Global Complaints; Bushra Khan; US Pharmacovigilance

Subject: Nitrosamine Testing Discrepancies- AUROBINDO

Importance: High

Good morning Megha,

The agency found discrepancies with the nitrosamine testing for API and FDP. The agency would like Aurobindo to test both the API and FDP at the same time, using the same analyst/method/equipment to eliminate any testing variance and provide those results to the FDA as soon as possible.

Aurobindo Valsartan - NDEA

Lab	Drug	NDMA	NDEA
OTR	Valsartan API (DMF 24544)	N.D.	N.D.
OTR	Valsartan FDP	N.D.	N.D0.592
Aurobindo	Valsartan FDP	N.D.	N.D0.686

- API tested negative, but FDP tested positive for NDEA
- Aurobindo recalled 80 lots of FDP

Aurobindo Losartan FDP - NDMA

Test results for Aurobindo losartan API and FDP

Lab	Firm	NDMA	NDEA
OTR	ZTP Losartan API (MF	N.D.	N.D.
	028346)		
OTR	Aurobindo API (MF	N.D.	N.D.
	019671)		
OTR	Aurobindo FDP	Up to 0.233	N.D.
Aurobindo	Aurobindo FDP	N.D.	N.D.

Losartan FDPs

Drug Name	ANDA	DMF	Notes	
Losartan Tablets	090083	019671	OTR testing shows FDP associated with	
			Aurobindo's API	
		028346	Appears that firm is claiming API from ZTP	
Losartan/HCTZ Tablets	091629	019671	OTR testing shows FDP associated with	
			Aurobindo's API	
		028346	Appears that firm is claiming API from ZTP	
		017728	DMF for HCTZ	

Thanks, your response is appreciated.

Case 1:19-md-02875-RMB-SAK Document 289-11 Filed 11/05/19 Page 3 of 3 PageID: 3486

Dellarese Herbert, R.N., B.S.N.
Lieutenant Commander, U.S. Public Health Service
U.S. Food & Drug Administration
Division Recall Coordinator/Compliance Officer
Division of Pharmaceutical Quality Operations I & IV
(CT, DC, DE, MA, MD, ME, NH, NJ, NY, PA, RI, VA, VT, WV, AK, AZ, CA, CO, HI, ID, MT, NM, NV, OR, UT, WA, WY)
900 U.S. Custom House, suite 904
200 Chestnut Street
Philadelphia, PA 19106

Phone: 215-717-3747 Blackberry 215-906-5589

Fax: 215-517-6649

email: dellarese.herbert@fda.hhs.gov

Orapharm1recalls@fda.hhs.gov, Serving CT, DC, DE, MA, MD, ME, NH, NJ, NY, PA, RI, VA, VT, WV Orapharm4recalls@fda.hhs.gov, Serving AK, AR, AZ, CA, CO, HI, ID, MT, NM, NV, OR, UT, WA, WY

"It takes many good deeds to build a good reputation, and only one bad one to lose it"